Search

everythingexperts & clinicslearnresearchcommunity

for

Search:↓

Tofacitinib and low-dose IL-2 may help maintain hair regrowth in alopecia areata without ongoing treatment.

Ruxolitinib effectively and safely regrows hair in alopecia patients.

The FDA approved a new Pfizer drug for hair loss in teens.

Cetuximab often causes skin problems, but they can be managed without stopping treatment.

Paclitaxel and nab-paclitaxel can be safe and effective for advanced gastric cancer patients on hemodialysis.

A medicine called tofacitinib worked to treat a hair loss condition linked with a muscle and skin disease.

Upadacitinib improved hair regrowth and quality of life in alopecia areata patients with minimal side effects.

Upadacitinib effectively treats psoriasis and lichen planus together.

Tofacitinib can help hair grow back in alopecia patients but hair loss might return if the dose is lowered.

Ritlecitinib is more effective and cheaper than baricitinib for treating severe alopecia areata.

CEP135 may predict cancer outcomes, and targeting PLK1 could help treat certain sarcomas.

Older patients with advanced kidney cancer can be managed with a drug called Sunitinib.

JAK1 inhibitor may effectively treat alopecia areata when TNF-α inhibitors and corticosteroids fail.

Janus kinase inhibitors are effective for severe alopecia areata, promoting hair regrowth.

Etanercept improved arthritis and psoriasis but caused hair loss, which healed after switching to sulfasalazine.

Tofacitinib significantly regrows hair in severe alopecia without major side effects.

Tofacitinib and baricitinib are similarly effective and safe for alopecia areata, but baricitinib works faster.

Oral and topical tofacitinib can effectively treat severe hair loss with minimal side effects.

High CCL11 levels may indicate poor response to baricitinib in severe alopecia areata.

Adding celecoxib to chemotherapy improves survival and quality of life for gastric cancer patients with positive COX-2.

Baricitinib helped regrow hair in patients with severe alopecia areata after other treatments failed.

New treatments may restore cancer-blocking proteins, slow prostate cancer, identify drug targets, and potentially regrow hair.

Ritlecitinib helps reduce inflammation and promote hair regrowth in alopecia areata, especially in patchy-type cases.

Activated ras can protect kidney cells from a certain substance that causes cell death.

Stopping erlotinib improved severe hair loss and skin issues in a patient.

Apraglutide and N-acetylcysteine (NAC) show promise in reducing cytarabine's harmful effects on organs.

Janus kinase inhibitors are promising for treating scarring alopecia, but more research is needed for safety and personalized treatments.